Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biowave Corp.

This article was originally published in Start Up

Executive Summary

Biowave hopes to ease the suffering of those with chronic pain with non-invasive and minimally invasive neuromodulation technology. Its devices--one designed for in-hospital use, one for home use--deliver a penetrating focused electrical field into deep tissue to block pain at its source.

You may also be interested in...



Neuromodulation: Devices's Stimulating Growth Market

According to "Opportunities in Global Medical Devices and Diagnostics," a report recently published by Health Research International that forecasts growth rates in seven major clinical segments and 20 major technology segments, neuromodulation will experience the highest growth rate of all the top-tier segments over the next five years, in excess of 18%. The neuromodulation segment posted sales of approximately $1.7 billion in 2005 and will be worth almost $4 billion in 2010, HRI predicts.

Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?

Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?

The Quality Lowdown: More Inspection Delays, More Findings On Sterility And Investigations

US FDA hits firms in New Jersey, South Korea and China with warning letters. Meanwhile, Catalent and several outsourcing facilities work on Form 483 inspection findings as Mylan, Viona and Lohxa announce drug recalls.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel